Quality of life in patients with chronic thromboembolic pulmonary hypertension

Stephen Mathai, Hossein Ardeschir Ghofrani, Eckhard Mayer, Joanna Pepke-Zaba, Sylvia Nikkho, Gérald Simonneau

Research output: Contribution to journalReview article

Abstract

Patients with chronic thromboembolic pulmonary hypertension (CTEPH) experience debilitating symptoms that have a negative impact on their quality of life (QoL) in terms of physical capability, psychological wellbeing and social relationships. The use of QoL measurement tools is important in the assessment of treatment efficacy and in guiding treatment decisions. However, despite the importance of QoL, particularly to the patient, it remains under-reported in clinical studies of CTEPH therapy. CTEPH is unique in pulmonary hypertension in that it is potentially curable by surgery; however, a proportion of patients either have residual PH following surgery or are not operable. Although some patients with CTEPH have been treated off-label with pulmonary arterial hypertension-specific therapies, there have been few randomised controlled trials of these therapies in patients with CTEPH. Moreover, in these trials QoL outcomes are variably assessed, and there is little consistency in the tools used. Here we review the assessment of QoL in patients with CTEPH and the tools that have been used. We also discuss the effect of surgical intervention and medical therapies on QoL. We conclude that further studies of QoL in patients with CTEPH are needed to further validate the optimal QoL tools.

Original languageEnglish (US)
Pages (from-to)526-537
Number of pages12
JournalEuropean Respiratory Journal
Volume48
Issue number2
DOIs
StatePublished - Aug 1 2016

Fingerprint

Pulmonary Hypertension
Quality of Life
Therapeutics
Randomized Controlled Trials
Psychology

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Quality of life in patients with chronic thromboembolic pulmonary hypertension. / Mathai, Stephen; Ghofrani, Hossein Ardeschir; Mayer, Eckhard; Pepke-Zaba, Joanna; Nikkho, Sylvia; Simonneau, Gérald.

In: European Respiratory Journal, Vol. 48, No. 2, 01.08.2016, p. 526-537.

Research output: Contribution to journalReview article

Mathai, S, Ghofrani, HA, Mayer, E, Pepke-Zaba, J, Nikkho, S & Simonneau, G 2016, 'Quality of life in patients with chronic thromboembolic pulmonary hypertension', European Respiratory Journal, vol. 48, no. 2, pp. 526-537. https://doi.org/10.1183/13993003.01626-2015
Mathai, Stephen ; Ghofrani, Hossein Ardeschir ; Mayer, Eckhard ; Pepke-Zaba, Joanna ; Nikkho, Sylvia ; Simonneau, Gérald. / Quality of life in patients with chronic thromboembolic pulmonary hypertension. In: European Respiratory Journal. 2016 ; Vol. 48, No. 2. pp. 526-537.
@article{12264808e68a4e3c9e908899c21c5553,
title = "Quality of life in patients with chronic thromboembolic pulmonary hypertension",
abstract = "Patients with chronic thromboembolic pulmonary hypertension (CTEPH) experience debilitating symptoms that have a negative impact on their quality of life (QoL) in terms of physical capability, psychological wellbeing and social relationships. The use of QoL measurement tools is important in the assessment of treatment efficacy and in guiding treatment decisions. However, despite the importance of QoL, particularly to the patient, it remains under-reported in clinical studies of CTEPH therapy. CTEPH is unique in pulmonary hypertension in that it is potentially curable by surgery; however, a proportion of patients either have residual PH following surgery or are not operable. Although some patients with CTEPH have been treated off-label with pulmonary arterial hypertension-specific therapies, there have been few randomised controlled trials of these therapies in patients with CTEPH. Moreover, in these trials QoL outcomes are variably assessed, and there is little consistency in the tools used. Here we review the assessment of QoL in patients with CTEPH and the tools that have been used. We also discuss the effect of surgical intervention and medical therapies on QoL. We conclude that further studies of QoL in patients with CTEPH are needed to further validate the optimal QoL tools.",
author = "Stephen Mathai and Ghofrani, {Hossein Ardeschir} and Eckhard Mayer and Joanna Pepke-Zaba and Sylvia Nikkho and G{\'e}rald Simonneau",
year = "2016",
month = "8",
day = "1",
doi = "10.1183/13993003.01626-2015",
language = "English (US)",
volume = "48",
pages = "526--537",
journal = "European Respiratory Journal, Supplement",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "2",

}

TY - JOUR

T1 - Quality of life in patients with chronic thromboembolic pulmonary hypertension

AU - Mathai, Stephen

AU - Ghofrani, Hossein Ardeschir

AU - Mayer, Eckhard

AU - Pepke-Zaba, Joanna

AU - Nikkho, Sylvia

AU - Simonneau, Gérald

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Patients with chronic thromboembolic pulmonary hypertension (CTEPH) experience debilitating symptoms that have a negative impact on their quality of life (QoL) in terms of physical capability, psychological wellbeing and social relationships. The use of QoL measurement tools is important in the assessment of treatment efficacy and in guiding treatment decisions. However, despite the importance of QoL, particularly to the patient, it remains under-reported in clinical studies of CTEPH therapy. CTEPH is unique in pulmonary hypertension in that it is potentially curable by surgery; however, a proportion of patients either have residual PH following surgery or are not operable. Although some patients with CTEPH have been treated off-label with pulmonary arterial hypertension-specific therapies, there have been few randomised controlled trials of these therapies in patients with CTEPH. Moreover, in these trials QoL outcomes are variably assessed, and there is little consistency in the tools used. Here we review the assessment of QoL in patients with CTEPH and the tools that have been used. We also discuss the effect of surgical intervention and medical therapies on QoL. We conclude that further studies of QoL in patients with CTEPH are needed to further validate the optimal QoL tools.

AB - Patients with chronic thromboembolic pulmonary hypertension (CTEPH) experience debilitating symptoms that have a negative impact on their quality of life (QoL) in terms of physical capability, psychological wellbeing and social relationships. The use of QoL measurement tools is important in the assessment of treatment efficacy and in guiding treatment decisions. However, despite the importance of QoL, particularly to the patient, it remains under-reported in clinical studies of CTEPH therapy. CTEPH is unique in pulmonary hypertension in that it is potentially curable by surgery; however, a proportion of patients either have residual PH following surgery or are not operable. Although some patients with CTEPH have been treated off-label with pulmonary arterial hypertension-specific therapies, there have been few randomised controlled trials of these therapies in patients with CTEPH. Moreover, in these trials QoL outcomes are variably assessed, and there is little consistency in the tools used. Here we review the assessment of QoL in patients with CTEPH and the tools that have been used. We also discuss the effect of surgical intervention and medical therapies on QoL. We conclude that further studies of QoL in patients with CTEPH are needed to further validate the optimal QoL tools.

UR - http://www.scopus.com/inward/record.url?scp=84979966415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979966415&partnerID=8YFLogxK

U2 - 10.1183/13993003.01626-2015

DO - 10.1183/13993003.01626-2015

M3 - Review article

VL - 48

SP - 526

EP - 537

JO - European Respiratory Journal, Supplement

JF - European Respiratory Journal, Supplement

SN - 0903-1936

IS - 2

ER -